ROCKVILLE, Md., Dec. 8, 2005 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF), a biotechnology company specializing in the research, development, licensing, and systems for treating non-healing chronic wounds including diabetic ulcers, today announced that the Kon-Lin Letter, a leading subscription-based stock market advisory service, has initiated coverage of the company in its December 2005 newsletter with an initial price target of $4.50-$5.50 per share and an ultimate target of $7.00-$9.00.
Kon-Lin is a 40-year-old publication noted for its fundamental and technical analysis of individual stocks and market movements. The Kon-Lin letter is provided as a subscription service only.
About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is the AutoloGel(tm) system, a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix. The company has concluded the treatment phase of a blinded, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers. Statements in this press release about the future growth of the market or the outcomes of the ongoing audit of the clinical trial results are examples of forward looking statements that may or may not come to fruition. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. Please note that any opinions, estimates or forecasts regarding Cytomedix's performance made by the Kon-Lin Letter are made only by the Kon-Lin Letter and do not represent opinions, forecasts or predictions of Cytomedix or its management. Cytomedix does not by its reference above imply its endorsement of, or concurrence with, such information, conclusions or recommendations. The Kon-Lin Letter is prepared by an independent third-party without the participation of or review by Cytomedix or its management. The company takes no responsibility for the opinions or accuracy of the Kon-Lin Letter, and states further that Cytomedix's actual results may differ materially from any opinions, estimates or forecasts from any source due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the success of new sales initiatives, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.